All In Biotech

Drug Trial Radar · NCT00262600

Randomized Evaluation of Long Term Anticoagulant Therapy (RE-LY) With Dabigatran Etexilate

Randomized Evaluation of Long Term Anticoagulant Therapy (RE-LY) Comparing the Efficacy and Safety of Two Blinded Doses of Dabigatran Etexilate With Open Label Warfarin for the Prevention of Stroke and Systemic Embolism in Patients With Non-valvular Atrial Fibrillation: Prospective, Multi-centre, Parallel-group, Non-inferiority Trial (RE-LY Study)

Last checked: Nov 20, 2026Latest source record: Apr 17, 2019 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 18,113 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

18,113

Actual

Start

Dec 2005

Primary completion

Apr 2009

Sponsor

Lead sponsor
Boehringer IngelheimBoehringer Ingelheim
Sponsor type
Industry
Collaborators
Population Health Research Institute; Uppsala University
First posted
Dec 7, 2005

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Primary purpose
Prevention
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The primary objective of this trial is to demonstrate the efficacy and safety of dabigatran etexilate in patients with non-valvular atrial fibrillation for the prevention of stroke and systemic embolism.

Conditions

  • Atrial Fibrillation
  • Stroke

Interventions

  • warfarinDrug

    once a day

  • Dabigatran dose 1Drug

    twice daily

  • Dabigatran dose 2Drug

    twice a day

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Yearly Event Rate for Composite Endpoint of Stroke/SEETime frame: 36 months

Locations

984 sites in 44 countries. Site status is shown where the registry gives one.

  • 1160.26.0009 Boehringer Ingelheim Investigational Site

    Birmingham, Alabama

  • 1160.26.0046 Boehringer Ingelheim Investigational Site

    Birmingham, Alabama

  • 1160.26.0057 Boehringer Ingelheim Investigational Site

    Birmingham, Alabama

  • 1160.26.0211 Boehringer Ingelheim Investigational Site

    Birmingham, Alabama

  • 1160.26.0206 Boehringer Ingelheim Investigational Site

    Huntsville, Alabama

  • 1160.26.0115 Boehringer Ingelheim Investigational Site

    Mobile, Alabama

  • 1160.26.0104 Boehringer Ingelheim Investigational Site

    Lake Havasu City, Arizona

  • 1160.26.0304 Boehringer Ingelheim Investigational Site

    Peoria, Arizona

  • 1160.26.0185 Boehringer Ingelheim Investigational Site

    Tucson, Arizona

  • 1160.26.0305 Boehringer Ingelheim Investigational Site

    Tucson, Arizona

  • 1160.26.0038 Boehringer Ingelheim Investigational Site

    Hot Springs, Arkansas

  • 1160.26.0302 Boehringer Ingelheim Investigational Site

    Jonesboro, Arkansas

  • 1160.26.0121 Boehringer Ingelheim Investigational Site

    Little Rock, Arkansas

  • 1160.26.0191 Boehringer Ingelheim Investigational Site

    Little Rock, Arkansas

  • 1160.26.0204 Boehringer Ingelheim Investigational Site

    Little Rock, Arkansas

  • 1160.26.0213 Boehringer Ingelheim Investigational Site

    Little Rock, Arkansas

  • 1160.26.0455 Boehringer Ingelheim Investigational Site

    Little Rock, Arkansas

  • 1160.26.0388 Boehringer Ingelheim Investigational Site

    Anaheim, California

  • 1160.26.0441 Boehringer Ingelheim Investigational Site

    Carmichael, California

  • 1160.26.0145 Boehringer Ingelheim Investigational Site

    French Camp, California

  • 1160.26.0333 Boehringer Ingelheim Investigational Site

    Fullerton, California

  • 1160.26.0384 Boehringer Ingelheim Investigational Site

    La Jolla, California

  • 1160.26.0091 Boehringer Ingelheim Investigational Site

    La Mesa, California

  • 1160.26.0246 Boehringer Ingelheim Investigational Site

    Lancaster, California

  • 1160.26.0345 Boehringer Ingelheim Investigational Site

    Larkspur, California

  • 1160.26.0217 Boehringer Ingelheim Investigational Site

    Loma Linda, California

  • 1160.26.0059 Boehringer Ingelheim Investigational Site

    Los Angeles, California

  • 1160.26.0088 Boehringer Ingelheim Investigational Site

    Los Angeles, California

  • 1160.26.0337 Boehringer Ingelheim Investigational Site

    Los Angeles, California

  • 1160.26.0326 Boehringer Ingelheim Investigational Site

    Mather, California

  • 1160.26.0070 Boehringer Ingelheim Investigational Site

    Merced, California

  • 1160.26.0349 Boehringer Ingelheim Investigational Site

    Oakland, California

  • 1160.26.0016 Boehringer Ingelheim Investigational Site

    Oceanside, California

  • 1160.26.0087 Boehringer Ingelheim Investigational Site

    Palm Springs, California

  • 1160.26.0459 Boehringer Ingelheim Investigational Site

    Pasadena, California

  • 1160.26.0216 Boehringer Ingelheim Investigational Site

    Redondo Beach, California

  • 1160.26.0135 Boehringer Ingelheim Investigational Site

    Riverside, California

  • 1160.26.0162 Boehringer Ingelheim Investigational Site

    Sacramento, California

  • 1160.26.0300 Boehringer Ingelheim Investigational Site

    Sacramento, California

  • 1160.26.0371 Boehringer Ingelheim Investigational Site

    Sacramento, California

Showing 40 of 984 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.